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Characterization of Point Mutations in the cdtA Gene of the Cytolethal Distending
Toxin of Actinobacillus Actinomycetemcomitans
Abstract
The Cdt is a family of gram-negative bacterial toxins that typically arrest eukaryotic cells in the G0/G1 or
G2/M phase of the cell cycle. The toxin is a heterotrimer composed of the cdtA, cdtB and cdtC gene
products. Although it has been shown that the CdtA protein subunit binds to cells in culture and in an
enzyme-linked immunosorbent assay (CELISA) the precise mechanisms by which CdtA interacts with
CdtB and CdtC has not yet been clarified. In this study we employed a random mutagenesis strategy to
construct a library of point mutations in cdtA to assess the contribution of individual amino acids to
binding activity and to the ability of the subunit to form biologically active holotoxin. Single unique amino
acid substitutions in seven CdtA mutants resulted in reduced binding of the purified recombinant protein
to Chinese hamster ovary cells and loss of binding to the fucose-containing glycoprotein, thyroglobulin.
These mutations clustered at the 5′- and 3′-ends of the cdtA gene resulting in amino acid substitutions
that resided outside of the aromatic patch region and a conserved region in CdtA homologues. Three of
the amino acid substitutions, at positions S165N (mutA81), T41A (mutA121) and C178W (mutA221)
resulted in gene products that formed holotoxin complexes that exhibited a 60% reduction (mutA81) or
loss (mutA121, mutA221) of proliferation inhibition. A similar pattern was observed when these mutant
holotoxins were tested for their ability to induce cell cycle arrest and to convert supercoiled DNA to
relaxed and linear forms in vitro. The mutations in mutA81 and mutA221 disrupted holotoxin formation.
The positions of the amino acid substitutions were mapped in the Haemophilus ducreyi Cdt crystal
structure providing some insight into structure and function.
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Summary
The Cdt is a family of gram-negative bacterial toxins that typically arrest eukaryotic cells in the
G0/G1 or G2/M phase of the cell cycle. The toxin is a heterotrimer composed of the cdtA, cdtB and
cdtC gene products. Although it has been shown that the CdtA protein subunit binds to cells in culture
and in an enzyme-linked immunosorbent assay (CELISA) the precise mechanisms by which CdtA
interacts with CdtB and CdtC has not yet been clarified. In this study we employed a random
mutagenesis strategy to construct a library of point mutations in cdtA to assess the contribution of
individual amino acids to binding activity and to the ability of the subunit to form biologically active
holotoxin. Single unique amino acid substitutions in seven CdtA mutants resulted in reduced binding
of the purified recombinant protein to Chinese hamster ovary cells and loss of binding to the fucosecontaining glycoprotein, thyroglobulin. These mutations clustered at the 5′- and 3′-ends of the
cdtA gene resulting in amino acid substitutions that resided outside of the aromatic patch region and
a conserved region in CdtA homologues. Three of the amino acid substitutions, at positions S165N
(mutA81), T41A (mutA121) and C178W (mutA221) resulted in gene products that formed holotoxin
complexes that exhibited a 60% reduction (mutA81) or loss (mutA121, mutA221) of proliferation
inhibition. A similar pattern was observed when these mutant holotoxins were tested for their ability
to induce cell cycle arrest and to convert supercoiled DNA to relaxed and linear forms in vitro. The
mutations in mutA81 and mutA221 disrupted holotoxin formation. The positions of the amino acid
substitutions were mapped in the Haemophilus ducreyi Cdt crystal structure providing some insight
into structure and function.

Introduction
The cytolethal distending toxin (Cdt) of the periodontal pathogen Actinobacillus
actinomycetemcomitans is a typical member of a family of secreted gram-negative bacterial
protein toxins that classically arrest the growth of many types of eukaryotic cells or cell lines
at either the G0/G1 or G2/M phase of the cell cycle (reviewed in references Pickett and
Whitehouse, 1999; Young and Schauer, 2000; Cortes-Bratti et al., 2001a; De Rycke and
Oswald, 2001; Lara-Tejero and Galán, 2002; De Rycke and Ducommun, 2003; Ohara et al.,
2004; Heywood et al., 2005; Oswald et al., 2005). Biologically active toxin, from many of the
diverse bacterial genera that express the Cdt, is a heterotrimer composed of approximately 18–
25 (CdtA), 31 (CdtB) and 21 (CdtC) kDa protein subunits expressed from a polycistronic
operon (Akifusa et al., 2001; Lara-Tejero and Galán, 2001; Saiki et al., 2001; Mao and
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DiRienzo, 2002; Lee et al., 2003; Shenker et al., 2004). One of the many intriguing
characteristics of the cdt genes is that they appear to have a eukaryotic rather than prokaryotic
heritage. The cdt gene products exhibit deduced amino acid sequence and structure/function
similarities (albeit weak) to those of eukaryotic proteins. Furthermore, introns have been
identified in the cdt operon of A. actinomycetemcomitans (Tan et al., 2005). The presence of
introns, typical of eukaryotic genes, is a rare occurrence in the eubacteria.
The toxic component of the holotoxin appears to be the CdtB protein subunit which has
similarity, based on position-specific iterated (PSI) BLAST (Altschul et al., 1997)
comparisons, to mammalian type I deoxyribonucleases (Elwell and Dreyfus, 2000; Lara-Tejero
and Galán, 2000; Lara-Tejero and Galán, 2002). Purified recombinant CdtB exhibits nicking
or relaxation activities, in vitro, when incubated with supercoiled DNA (Elwell and Dreyfus,
2000; Elwell et al., 2001). DNA damage in the form of double-stranded breaks, as assessed by
pulsed-field gel electrophoresis (PFGE), was detected in sensitive cell types exposed to the
holotoxin (Cortes-Bratti et al., 2001b; Frisan et al., 2003; Kanno et al., 2005). Mutating
conserved DNase I active site residues in CdtB resulted in the loss of both in vitro nuclease
activity and in vivo cell cycle arrest (Elwell and Dreyfus, 2000; Lara-Tejero and Galán,
2000).
The CdtA protein subunit also appears to be related to eukaryotic proteins. Based on the initial
observations reported by Hofmann et al. (2000) and Hassane et al. (2001), amino acid sequence
threading analysis (Lara-Tejero and Galán, 2001) and a reverse position-specific (RPS)BLAST search of the conserved domain (CD) database (Mao and DiRienzo, 2002) functional
similarity was noted between a 60–88 sequence of amino acids in CdtA and the B chain of
members of the ricin/abrin A–B toxin family. The B chain of ricin acts in a lectin-like
interaction attaching to carbohydrate receptors on the cell surface to promote uptake of the A
chain of the toxin (Rutenber et al., 1987). Data from immunofluorescence experiments (Mao
and DiRienzo, 2002; Akifusa et al., 2005; McSweeney and Dreyfus, 2005; Kanno et al.,
2005) and enzyme-linked immunosorbent assays on live cells (CELISA) (Lee et al., 2003)
experiments showed that purified recombinant CdtA binds to cells in culture.
A specific eukaryotic connection for the CdtC subunit protein has not been found. However,
CdtC has significant amino acid sequence similarity with CdtA (40% for the Campylobacter
jejuni deduced amino acid sequences; Pickett and Whitehouse, 1999; Lee et al., 2003)
suggesting a common function. Purified recombinant CdtC also binds to HeLa (McSweeney
and Dreyfus, 2005) and HEp-2 (Akifusa et al., 2005) cells in culture and to HeLa cells in the
CELISA (Lee et al., 2003). It has recently been shown that both CdtA and CdtC from
Escherichia coli are carbohydrate-binding proteins that recognize N-linked fucose moieties on
the surface of HeLa cells (McSweeney and Dreyfus, 2005).
The Cdt of Haemophilus ducreyi has been crystalized (NeŠić et al., 2004). The crystal structure
supports a ternary complex having three interdependent molecular interfaces. The CdtA and
CdtC subunits interact to form two ricin-like lectin domains separated by a deep groove. There
is a highly aromatic surface on the CdtA face of the groove. Mutating four aromatic residues
(quadruple mutant) in the aromatic patch domain of the CdtA subunit produced a non-toxic
reconstituted holotoxin.
Mutagenesis approaches are invaluable for studying the relationship between structure and
function. Insertional inactivation of the CdtA gene using antibiotic resistance gene cassette or
transposon (TnphoA, Tn5) insertions has been used to demonstrate that this subunit is an
important component of the holotoxin (Scott and Kaper, 1994; Lewis et al., 2001; Mao and
DiRienzo, 2002; Young et al., 2004). In-frame deletions and site-directed mutagenesis of
cdtA have provided more detailed information about the role of putative functional regions in
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the protein subunit (Lee et al., 2003; NeŠić et al., 2004; Saiki et al., 2004). However, there is
still a great deal to be learned about the molecular details of the interactions between CdtA and
the CdtB and CdtC subunits and between CdtA and cell surface receptors.
To advance studies of the function and interactions of the CdtA subunit and to identify single
amino acid residues critical for CdtA activity, we made a library of randomly generated point
mutations. Mutants with unique single amino acid substitutions were examined for changes in
binding of isolated recombinant CdtA to Chinese hamster ovary (CHO) cells. Holotoxin was
reconstituted with each mutated cdtA gene product and tested for the ability to inhibit CHO
cell proliferation, to promote cell cycle arrest and to exhibit DNase I-like nicking activity in
vitro. Each mutated cdtA gene product was also tested for the ability to bind to fucosecontaining glycoproteins, to compete with wild-type CdtA for binding to CdtB and CdtC and
to form a holotoxin complex. The greater than 90% similarity between the deduced amino acid
sequences of the CdtA proteins of A. actinomycetemcomitans and H. ducreyi (Cope et al.,
1997; Sugai et al., 1998; Mayer et al., 1999) allowed us to map the positions of the amino acid
substitutions in the H. ducreyi Cdt crystal structure. The implications of specific amino acid
substitutions on predicted relationships between structure and function are discussed.

Results
Selection of point mutations in cdtA and isolation of the mutants
A library of randomly generated point mutations was constructed in the plasmid vector pET15b.
The His-tag DNA sequence was removed from the plasmid vector and six codons for histidine
were placed in the reverse polymerase chain reaction (PCR) primer used to generate the mutant
sequences (Table 1). These steps ensured that full length cdtA gene sequences could be easily
identified in the mutant library by screening for the presence of the His-tag on the gene products.
The pJDA9 construct (Table 2), encoding wild-type CdtA, was used as the template for
mutagenesis and served as a positive control for all experiments. Mutations were introduced
at a very low frequency to enhance chances of recovering mutants having a single nucleotide
change. Total cell lysates of transformants carrying potential mutated cdtA gene sequences
were first screened in a CELISA for reduction in binding to CHO cells relative to an E. coli
lysate containing wild-type CdtA. This initial screening assay facilitated the analysis of a large
number of potential mutants and provided a positive selection method for loss of biological
activity. Those transformants that demonstrated binding at levels below that of the wild-type
recombinant strain where examined for the correct size DNA insert by either restriction
endonuclease mapping or by PCR. Those transformants that had the expected size plasmid
DNA insert (668 bp) were then checked for expression of the cloned gene by Western blotting
employing a monoclonal antibody that recognized the carboxy-terminal His-tag. Plasmid DNA
from those transformants that contained an immuno-positive polypeptide, having an apparent
molecular weight of approximately 27 kDa, were then subjected to DNA sequencing to confirm
and identify the mutation.
Identification and validation of the point mutations
Of 192 transformants, selected at random following mutagenesis, five failed to grow. Sixtysix transformants exhibited binding in the CELISA comparable to that of the negative control.
Twenty-six of these 66 transformants had no insert DNA in the plasmid. Of the 40 remaining
transformants 21 had very low level expression of CdtA after IPTG induction resulting in a
binding-deficient phenotype. As it would not be feasible to recover significant quantities of
gene product from these transformants for testing in the bioassays they were not studied further.
The plasmid DNA inserts from the remaining 19 transformants were sequenced. Reliable DNA
sequence data could not be retrieved, from two to three sequencing runs, from six of the 19
transformants. The remaining 13 transformants expressed a full length cdtA open reading frame
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(ORF). Two of these transformants (mutA65 and mutA112) each had two nucleotide changes.
Only one of these nucleotide changes in both mutA65 and mutA112 resulted in an amino acid
substitution. Eleven transformants had a single nucleotide change. Six of these transformants
had a corresponding amino acid change. Two transformants (mutA241 and mutA249) had the
same nucleotide change (A655G) and corresponding amino acid substitution (T219A). The
mutants are listed in Table 3. The cdtA ORFs from seven of the transformants that exhibited
binding in the CELISA equivalent to that of the wild type (pJDA9) were also sequenced. No
nucleotide changes were found.
The hydropathies of the mutant CdtA-His6 proteins were compared with that of the wild-type
protein. Hydropathy was increased in the region surrounding the substituted residues in
mutA121T41A and mutA241T219A Hydropathy was decreased in the regions surrounding the
substituted residues in mutA65C197S, mutA81S165N, mutA112F43S, mutA221C178W and
mutA239P56Q The calculated pI of wild-type CdtA-His6 was 8.2164. The pI of
mutA65C197S and mutA221C178W was 8.3192. All the other mutant proteins had a pI identical
to that of the wild type.
Effect of cdtA point mutations on subunit binding
Wild-type CdtA-His6 demonstrated saturation binding kinetics with CHO cells in the CELISA
(Fig. 1A). No difference was observed between the binding of CdtA labelled at either the
amino- or carboxy-terminal end of the protein (data not shown). CdtA-His6 was isolated by
affinity chromatography from the seven mutants (Table 3) that had confirmed unique single
amino acid substitutions. Binding of the isolated mutant proteins to CHO cells was measured
in the CELISA and compared with that of the wild-type CdtA-His6 (Fig. 1B). All seven mutant
proteins exhibited a statistically significant reduction in binding (P < 0.005 for six mutants,
P < 0.01 for one mutant). CdtA-His6 was also isolated from one of the mutants (mutA99) that
had a single nucleotide change (T264A) but no corresponding amino acid substitution (Table
3). No statistically significant reduction in binding, relative to the wild-type CdtA-His6, was
observed with the gene product from this mutant (Fig. 1B). The analysis of mutA99
demonstrated that using crude bacterial extracts in the CELISA can give false positive results
and explains why CdtA from five of 11 binding-deficient clones had no amino acid
substitutions.
A second binding assay based on immobilized fucose-containing glycoproteins in an ELISA
was used to support the CELISA results. Cdt subunit protein binding to thyroglobulin was
similar to that observed with CHO cells. Wild-type CdtA-His6 demonstrated saturation kinetics
(Fig. 2A). Wild-type CdtB-His6 and CdtC-His6 did not bind and bound poorly respectively.
All seven CdtA mutant proteins failed to bind to thyroglobulin (P < 0.005; Fig. 2B). Binding
of CdtA-His6 from mutA99 again was not statistically different than that of the wild-type
protein.
Effect of cdtA point mutations on the activities of reconstituted holotoxin
Reconstituted wild-type holotoxin exhibited a dose dependent effect on the proliferation of
CHO cells (Fig. 3A). A TD50 was obtained with 1 μg ml−1 of reconstituted holotoxin.
Reconstituted holotoxins were prepared in a 1:1:1 ratio using the mutant CdtA-His6 tagged
protein subunits and wild-type subunits CdtB-His6 and CdtC-His6. Cultures of CHO cells were
treated with the various mutant CdtA-containing holotoxins for 36 h and cell survival was
compared with that of cultures treated with holotoxin reconstituted with the wild-type CdtAHis6 (Fig. 3B). Holotoxins made with protein from four of the mutants (mutA65, mutA112,
mutA239 and mutA241), and wild-type holotoxin (CdtA-H), inhibited proliferation of CHO
cells by 95–100%. Holotoxin prepared with CdtA-His6 from mutA81 reduced CHO cell
proliferation by 60%. Holotoxins reconstituted with protein from mutA121 and mutA221 had
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no detectable effect on proliferation (100% of the input cells survived). CHO cells were also
treated with double the concentration (5.0 μg ml−1) of holotoxins reconstituted with protein
from mutA81, mutA121 and mutA221 (Fig. 3B, bars labelled 5). The difference in the results
were negligible. Holotoxin made with protein from mutA99 (no amino acid substitution)
inhibited CHO cell proliferation by 100%. To demonstrate that these results were not an artifact
or anomaly associated with CdtA, holotoxins were reconstituted with protein from both
mutA81 and mutC41 as well as with wild-type CdtA-His6 and the CdtC-His6 protein from
mutC41. The cdtC gene in mutC41 contains four nucleotide changes, two of which have
corresponding amino acid substitutions (Q49L and S173C) in the gene product. Both of these
hybrid holotoxins had no effect on CHO cell proliferation (Fig. 3B).
To further support the observation that several of the CdtA-His6 mutant proteins yielded
holotoxins that failed to exhibit biological activity, CHO cell cultures were treated with wildtype and mutant CdtA-containing holotoxin and examined by flow cytometry. CHO cell
cultures treated for 36 h with increasing concentrations of wild-type holotoxin showed a dose
dependent increase in the percent of cells having a 4n DNA content indicative of arrest at the
G2/M phase (Fig. 4A panels a–e). Greater than 90% of the cells (1 × 106 cells treated) had a
4n DNA content when exposed to 10 μg ml−1 of wild-type holotoxin (Fig. 4B). A TD50 was
obtained with approximately 4 μg ml−1 of reconstituted holotoxin. FACS analysis of CHO cell
cultures treated with holotoxin reconstituted with each of the mutant CdtA-His6 protein
subunits gave results that paralleled exactly those of the proliferation assay (Fig. 4C). The
percentage of CHO cells having a 4n DNA content following exposure to holotoxins made
with mutant CdtA-His6 protein from mutA81 (panel b), mutA121 (panel e) and mutA221
(panel f) was 44, 10 and 15, respectively, compared with 66% for cells treated with wild-type
toxin (Table 4). Exposure of CHO cells to equivalent concentrations of holotoxins made with
mutA65, mutA112, mutA239 and mutA241 CdtA-His6 proteins yielded 70–79% of the cell
population with a 4n DNA content. Only 15% of the cell population had a 4n DNA content
following treatment with holotoxin made with wild-type CdtA-His6 and CdtB-His6 and cdtC
gene product from mutC41 (panel i).
It has been shown that wild-type or properly assembled holotoxin has diminished in vitro DNA
nicking activity presumably due to inhibition of CdtB by the N-terminal tail of correctly
assembled CdtC (NeŠić et al., 2004). Taking advantage of this semi-quantitative approach,
holotoxins reconstituted with recombinant wild-type CdtA-His6 and the CdtA-His6 mutant
proteins were examined for the ability to convert supercoiled plasmid DNA to linear and
relaxed forms. Holotoxin composed of wild-type subunit proteins had no supercoiled DNA
nicking activity relative to CdtB-His6 alone (Fig. 5A). The nicking activity of CdtB-His6 was
not affected when this subunit was mixed with either CdtA-His6 or CdtC-His6. CdtA-His6 and
CdtC-His6 proteins, alone and in combination, did not display DNA nicking activity.
Holotoxins prepared with mutant CdtA-His6 proteins from mutA121 and mutA221 converted
all the supercoiled DNA to relaxed and linear forms (Fig. 5B). This was comparable to the
nicking activity observed with the free CdtB-His6 subunit and was suggestive of altered
holotoxin reconstitution. Holotoxins made with mutant CdtA-His6 proteins from mutA65,
mutA81, mutA112, mutA239 and mutA241 showed varying degrees of inhibition of DNA
nicking activity. These data indicated that holotoxin reconstitution was altered but not to the
extent that CdtB DNA nicking activity was completely inhibited. As expected, the nicking
activity of holotoxin made with protein from mutA99 (no amino acid substitution) was
inhibited indicative of proper (wild-type) holotoxin assembly. Holotoxin made with mutC41
protein did not exhibit DNA nicking activity (Fig. 5B). However, when both mutA81 and
mutC41 were used to make reconstituted holotoxin all of the supercoiled DNA was converted
to relaxed form. These results with the CdtA-His6 mutant proteins followed the pattern of
inhibition or loss of inhibition of activity observed in the other functional assays.
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Two additional methods were used to determine if the mutant CdtA-His6 proteins formed
reconstituted holotoxin. In the first method, the thyroglobulin ELISA, shown in Fig. 2 that is
based on the binding of CdtA to fucose-containing glycoproteins (McSweeney and Dreyfus,
2005), was used to evaluate the ability of the mutant proteins to compete with wild-type CdtAHis6 for binding to CdtB-His6 and CdtC-His6. Results from this assay using combinations of
wild-type subunit proteins showed that the binding of the subunits was specific and additive
(Fig. 6A). An increase in the absorbance following binding of CdtB-His6 to CdtA-His6 in the
absence of CdtC-His6 was not statistically significant (absorbance ratio of 1.2). However, the
increase in absorbance following binding of CdtC-His6 to CdtA-His6 in the absence of CdtBHis6 was significant (P < 0.01) and had an absorbance ratio of 1.5. When all three subunit
proteins were combined the increase in absorbance was statistically significant (P < 0.005) and
the absorbance ratio was 3.0. These results demonstrated that all three subunits were bound
and that CdtA and CdtC binding was required for binding of CdtB. In competition experiments
CdtA-His6 from mutA99, mutA112, mutA121 and mutA239 showed no increase in absorbance
(absorbance ratios 1.0–1.4) relative to wild-type CdtA alone suggesting that these mutant
proteins formed holotoxin (Fig. 6B). CdtA-His6 from mutA65, mutA81, mutA221 and
mutA241 had absorbance ratios below 3.0 (1.8–2.6) suggesting that they may form aberrant
or partial holotoxin complexes.
A second assay for reconstitution was based on the size-dependent retention of reconstituted
holotoxin (estimated molecular weight of 77 kDa) in dialysis tubing that has a 100 kDa
molecular weight cut-off. Holotoxin was reconstituted with wild-type and mutant CdtA-His6
proteins and then dialysed for 48 h at 4°C. The material retained in the dialysis bag was then
examined on Western blots. Figure 7A shows that the individual Cdt subunit proteins
(estimated molecular weights of 21–31 kDa) and preincubated mixtures of wild-type CdtAHis6 and CdtC-His6 (heterodimer) were not retained following dialysis. In contrast, all three
wild-type subunit proteins were detected in the dialysis bag, on Western blots, when
reconstituted holotoxin (heterotrimer) was used. All three subunit proteins were retained
following dialysis (approximately 100% of each protein retained) when CdtA-His6 from
mutA121 was substituted for the wild-type protein (Fig. 7B). This result supported heterotrimer
formation by this mutant CdtA protein. However, when CdtA-His6 from mutA221 was used
to form holotoxin greater than 75% of CdtB and CdtC and 46% of CdtA were lost from the
bag following dialysis (Fig. 7B). Approximately 38%, 31% and 64% of CdtA, CdtB and CdtC,
respectively, were not retained when CdtA-His6 from mutA81 was used to make holotoxin.
Reconstituted mixtures containing the other CdtA-His6 mutant proteins, which were all active
in the bioassays, were trapped in the dialysis bag (data not shown). These results were in good
agreement with those from the competition assay. A mixture of CdtA-His6 from mutA121,
CdtC-His6 from mutC41 and wild-type CdtB-His6 was not trapped following dialysis
indicating that a holotoxin complex was not formed by this combination of mutant subunits.
Mapping amino acid substitutions that alter CDT activity in the holotoxin structure
The amino acid sequences of CdtA from A. actinomycetemcomitans and H. ducreyi are greater
than 91% similar (Cope et al., 1997; Sugai et al., 1998; Mao and DiRienzo, 2002). Figure 8
shows an alignment of the A. actinomycetemcomitans and H. ducreyi CdtA (GenBank
Accession number U53215) deduced amino acid sequences. A single gap was introduced in
the A. actinomycetemcomitans CdtA sequence at the position of amino acid residue 64 to obtain
the alignment. There are 18 conserved amino acid differences between the A.
actinomycetemcomitans and H. ducreyi native CdtA. Three of the A.
actinomycetemcomitans CdtA mutations (mutA121, mutA112 and mutA239) were at positions
that had conserved amino acid differences relative to the H. ducreyi CdtA. The other four CdtA
mutations were at positions that were identical in the two protein sequences. However, due to
the gap in the A. actinomycetemcomitans sequence at position 64 the H. ducreyi sequence is

Mol Microbiol. Author manuscript; available in PMC 2006 April 10.

Cao et al.

Page 7

out of register by one amino acid after this position. Two of the mutants (mutA65 and mutA221)
contained a substitution for a cysteine residue at positions C179 and C198, respectively, in the
A. actinomycetemcomitans sequence.
Recent publication of the crystal structure of the H. ducreyi Cdt (NeŠić et al., 2004) provided
a model for mapping the positions of the substituted residues that alter CdtA binding and
holotoxin activity. The crystal structure of the H. ducreyi Cdt is shown in Fig. 9. Panels A–C
illustrate the relationship of the CdtA, CdtC and CdtB subunits respectively. The seven unique
mutations in the A. actinomycetemcomitans CdtA are mapped on the structure (Fig. 9D). The
three mutants mutA121, mutA112 and mutA239, with amino acid substitutions corresponding
to the H. ducreyi CdtA positions I41, P43 and S56, respectively, contained substituted residues
at the amino terminal end of the protein that was not resolved in the crystal structure. All three
of these mutants had a binding-deficient phenotype and were the strongest competitors
(absorbance ratio ≈ 1) of wild-type CdtA binding to CdtB and CdtC. Only one of these amino
terminal point mutations (mutA121T41A), corresponding to position I41 (underlined) in the H.
ducreyi CdtA protein, also abolished proliferation inhibition activity and the ability to send
cells into G2/M arrest when incorporated into reconstituted holotoxin. The other four mutations
(mutA65C197S, mutA81S165N, mutA221C178W and mutA241/249T219A) were closer to the
carboxy-terminal end of the CdtA protein. All of these mutants had a binding-deficient
phenotype and competed (absorbance ratios 1.8–2.6) against wild-type CdtA for binding to
CdtB and CdtC. Two of the carboxy-terminal point mutations (mutA81S165N and
mutA221C178W), corresponding to positions S166 and C179 (underlined), respectively, in the
H. ducreyi CdtA protein, resulted in a reduction or loss of proliferation inhibitory activity and
the ability to send cells into G2/M arrest. All seven unique mutations reside outside of the
aromatic patch region (Fig. 9E).

Discussion
A number of investigations have provided evidence implicating the CdtA and CdtC subunits
in the binding of Cdt to cells. Frisk et al. (2001) found all three recombinant Cdt proteins
absorbed to the surface of HEp-2 cells. However, a 17 kDa form of CdtA was the predominant
bound species. Direct evidence of CdtA binding to cells was obtained from
immunofluorescence experiments (Mao and DiRienzo, 2002; Akifusa et al., 2005; McSweeney
and Dreyfus, 2005; Kanno et al., 2005) and CELISA (Lee et al., 2003). These studies examined
the ability of purified recombinant CdtA subunit protein and reconstituted holotoxin to bind
to CHO and HeLa cells respectively. Deng and Hansen (2003) detected CdtC attached to HeLa
cells in cultures treated with a CdtA–CdtC complex. However, they could not detect bound
CdtC when the same cells were treated with this subunit alone. McSweeney and Dreyfus
(2005) showed that CdtA and CdtC bound to agarose bead-immobilized fucose-containing
glycoproteins, such as thyroglobulin. We observed that CdtA-His6 bound with saturation
kinetics to thyroglobulin-coated ELISA plates (this study). However, CdtC-His6 bound very
poorly under the same conditions unless added to the plates together with CdtA-His6.
Although it is now well established that all three Cdt subunits are required for the toxin to
manifest its cell inhibitory effects in vivo (Pickett et al., 1994; Sugai et al., 1998; Deng et al.,
2001; Frisk et al., 2001; Lara-Tejero and Galán, 2001; Saiki et al., 2001; Mao and DiRienzo,
2002), several studies have shown that CdtB and CdtC reconstituted in vitro manifests
biological activity. HEp-2 cells exposed to a recombinant A. actinomycetemcomitans Cdt
reconstituted with CdtB and CdtC were arrested at the G2/M phase of the cell cycle (Akifusa
et al., 2001). This result was confirmed with purified recombinant C. jejuni Cdt subunit proteins
and HeLa cells (Lee et al., 2003). However, cell cycle arrest was reduced by 75% when
reconstituted holotoxin lacked CdtA. It seems clear that there is an interaction between CdtA
and either or both CdtC and CdtB subunits that is required to produce a holotoxin that has
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optimal biological activity (Deng and Hansen, 2003; Lee et al., 2003; NeŠić et al., 2004;
Shenker et al., 2005). CdtA and CdtC may compete for binding to the same fucose-containing
cell surface receptor (McSweeney and Dreyfus, 2005) supporting the possibility that these two
subunits act in concert in vivo to bind toxin to the cell surface. In addition, CdtC appears to be
required for internalization of CdtB (Akifusa et al., 2005). However, the precise mechanisms
by which CdtA and CdtC each contribute to toxin binding have not yet been clarified.
Deletion mutants and site-directed mutagenesis methods have been employed to provide more
detailed information about the binding specificity of CdtA. An in-frame deletion in the C.
jejuni CdtA, removing amino acids 126–168, did not affect the ability of the reconstituted toxin
to arrest HeLa cells, did not reduce binding of the purified subunit protein to these cells in
CELISA and competed for binding to these cells with holotoxin containing wild-type CdtA
(Lee et al., 2003). This 43 amino acid region is conserved among CdtA proteins in various
bacterial species. Apparently, deletion of this conserved region does not affect the biological
activity of the toxin. In another study, a series of in-frame deletion mutants lacking amino acids
19–38, 19–47, 19–57, 19–77 and 19–88 was constructed (Saiki et al., 2004). Deletion mutants
CdtAΔ19–38 and CdtAΔ19–47 did not affect the ability of the CdtA mutant proteins to make
fully active holotoxin. NeŠić et al. (2004) used site-directed mutagenesis to make substitutions
for four aromatic amino acids (W91G, W98G, W100G and W102A), in a single mutant, in the
aromatic patch region of the H. ducreyi CdtA. Recombinant Cdt made with this aromatic patch
mutant failed to arrest HeLa cells at the G2/M phase of the cell cycle but did not disrupt stability
of the holotoxin as measured by gel filtration chromatography.
In the current study we employed a random mutagenesis strategy to construct a library of point
mutations in cdtA to assess the contribution of individual amino acids to the binding activity
of the subunit and to the ability of the subunit to form active holotoxin. A random mutagenesis
strategy rather than a targeted strategy was used initially because, except for the aromatic patch
region, no other binding or functional domains have been identified in CdtA. We obtained
seven CdtA mutants, with unique point mutations, that produced subunit proteins that had
dramatically reduced binding to CHO cells and thyroglobulin. Three of these mutations
(mutA121T41A, mutA112F43S and mutA239P56Q) resulted in amino acid substitutions in the
amino-terminal region of the protein (corresponding to H. ducreyi CdtA positions I41, P43 and
S56, respectively, see Fig. 8). This region (residues 18–56) is disordered in the H. ducreyi Cdt
crystal structure so it is difficult to make predictions about the relationship between the
locations of the amino acid substitutions and binding activity (NeŠić et al., 2004 and Fig. 9D.
It has been proposed that the amino-terminus of CdtA inserts deep in the groove formed
between CdtA and CdtC in the crystal structure and may mimic a receptor peptide (NeŠić et
al., 2004). However, it is possible that the amino terminus of CdtA is important for formation
of the groove and therefore may be essential for recognition of the cell surface receptor. If that
is the case the amino acid substitutions in mutA121T41A, mutA112F43S and mutA239P56Q may
alter the ability of the amino-terminus to fold properly thus changing or masking the CdtA face
of the groove. We did not obtain binding-deficient mutants with amino acid substitutions at
positions prior to residue 41. This is in good agreement with the previous observation that inframe deletion of residues 19–47 did not alter toxin activity (Saiki et al., 2004). In that study
a dramatic loss of Cdt activity was observed with the next largest deletion in the series (residues
19–57). It is not surprising that deletion of the amino-terminus up to amino acid 47 does not
affect Cdt activity because there are indications that CdtA is post-translationally processed by
both A. actinomycetemcomitans and E. coli (Sugai et al., 1998).
The other four binding-deficient mutants (mutA81S165N, mutA221C178W, mutA65C197S and
mutA241/249T219A) contained amino acid substitutions toward the carboxy-terminal region
of the protein (corresponding to H. ducreyi CdtA positions S166, C179, C198 and T220,
respectively, see Fig. 8). No mutants containing amino acid substitutions in the aromatic patch
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region were obtained (see Fig. 9D and E). The reason for this result is most likely due to our
screening method which selected mutants that had a CdtA binding-deficient phenotype. The
aromatic patch mutant reported by NeŠić et al. (2004) lost the ability to arrest HeLa cells but
not to affect the ability of the mutant protein to form holotoxin. Our data show that single amino
acid substitutions outside of the aromatic patch region can affect the binding of free CdtA to
cells and to fucose-containing glycoprotein. Several of these mutations affect but do not abolish
the ability of CdtA to bind to the other subunits. Two of these mutations (mutA65C197S and
mutA221C178W) replaced cysteine residues (corresponding to H. ducreyi CdtA positions C179
and C198, respectively, see Figs 8 and 9F).
Three (mutA81S165N, mutA121T41A and mutA221C178W) of the seven CdtA binding-deficient
mutants exhibited significantly altered biological activities yet they apparently formed a
holotoxin complex with CdtB and CdtC. These mutations contained substituted amino acids
at positions I41 (mutA121T41A) in the amino-terminal region and S166 (mutA81S165N) and
C179 (mutA221C178W) in the carboxy-terminal region of the H. ducreyi CdtA (see Figs 8 and
9D). The mutation in mutA121 is particularly interesting because the CdtA-His6 gene product
was a strong competitive inhibitor of wild-type CdtA-His6 binding to CdtB-His6 and CdtCHis6 yet holotoxin made with this mutant protein lacked biological activity. The amino acid
switch alanine for threonine in mutA121 was relatively conservative in terms of potential
physical changes in the protein. There was a slight increase in the relative hydropathy around
residue 41 of the altered gene product. However, the calculated pI of the mutant protein was
identical to that of the wild-type protein. It is possible that the threonine in this position is
important for the recognition of the N-linked fucose-containing cell surface receptor. In
contrast, a switch from phenylalanine to serine at neighbouring position 43 (mutA112) did not
affect the biological activity of the subunit. This was a more radical mutation in which a nonreactive amino acid replaced an aromatic residue.
MutA81 is also an interesting mutant because there were partial effects on the cell proliferation
inhibition, cell cycle arrest and CdtB DNA nicking activities of holotoxin made with this CdtAHis6 protein. This partial loss of activity correlated with a reduced ability to form heterotrimer.
There was a switch from serine to asparagine at position 165 in mutA81. The change from a
neutral to acidic amino acid could be significant. However, there was no change in the
calculated pI of the mutant protein compared with that of the wild-type protein. The mutation
resulted in a slight decrease in the relative hydropathy surrounding this residue. Position 165
in CdtA in the H. ducreyi Cdt crystal structure is close to the end of the conserved region in
CdtA proteins (Lee et al., 2003). Other than mutA81S165N, we did not find binding-deficient
mutations with amino acid substitutions in this conserved region. These findings support the
results obtained by Lee et al. (2003) with their 43 amino acid deletion mutant.
An amino acid substitution at position 178 in CdtA (mutA221) also resulted in the loss of
holotoxin activity. This residue (C179) in the H. ducreyi crystal structure is not near the putative
receptor groove between CdtA and CdtC nor does it appear to be in contact with the CdtB
subunit. However, it is likely that an intrachain disulphide bridge between C179 and C198 was
disrupted (see Fig. 9F). The substitution in mutA221 was a switch from cysteine to tryptophan.
Not only was a reactive cysteine residue removed but it was replaced with a large heterocyclic
amino acid. The amino acid switch increased the pI of the protein and decreased the hydropathy
of the region around residue 178. However, it is interesting to note that a more reserved cysteine
substitution in mutA65C197S did not affect the biological activity of CdtA. This mutant protein
had a increased calculated pI (same as that of mutA221C178W) and reduced hydropathy relative
to the wild-type protein. Based on the difference between the activities of holotoxins
reconstituted with protein from mutA221C178W and mutA65C197S, it appears that a disulphide
bridge in this region of CdtA may not be required for optimum Cdt activity. The loss of activity
in holotoxin made with protein from mutA221C178W is more likely due to the introduction of
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a large reactive amino acid that changes the folding of CdtA so that it no longer forms a
holotoxin complex. This is supported by the results of the competition experiments in which
this mutant protein was a relatively weak competitive inhibitor of wild-type CdtA-His6 binding
to the other subunits and the dialysis experiments.
In summary, we have identified point mutations in the cdtA gene of the A.
actinomycetemcomitans Cdt that reduce or abolish binding of the subunit protein to CHO cells
and fucose-containing glycoproteins such as thyroglobulin. These mutations resulted in amino
acid substitutions that clustered at the amino- and carboxy-terminal regions of the protein.
Three of these point mutations resulted in a statistically significant reduction or loss of
biological activity of reconstituted holotoxin. Therefore, mutations that affect subunit binding
to cells and receptor-like glycoproteins can reside outside of the aromatic patch region. Several
of the point mutations resulted in gene products that formed holotoxin complexes that lost the
ability to arrest cell growth. In the case of some, but not all of these mutations, the loss of
activity could be due to the inability of the mutant protein to properly assemble. The next step
is to use a site-directed mutagenesis approach to determine if these mutations reside in more
extensive domains in CdtA critical for proper holotoxin assembly and binding to the cell
surface.

Experimental procedures
Plasmids and oligonucleotide primers
Based on the sequence of the cdt locus of A. actinomycetemcomitans Y4 (Mayer et al., 1999;
GenBank Accession number AF006830), synthetic oligonucleotide primer pairs (Table 1) were
designed and used to amplify the three cdt gene sequences. Plasmid pCDT1 (Mayer et al.,
1999), containing the cdtABC ORFs cloned in pBluescript II SK(+) (Stratagene, La Jolla, CA)
was used as template DNA. Oligonucleotide primers were purchased from Integrated DNA
Technologies (IDT, Coralville, IA). Codons for six histidine residues (His-tag) were added to
the 3′-end of each CdtA, CdtB and CdtC gene sequence using the reverse primers (bases in
bold type in Table 1). Products amplified by PCR were cloned into the NcoI and BamHI sites
(underlined bases in Table 1) of pET15b (Novagen, EMD Biosciences, San Diego, CA) so that
the His-tag in the vector was removed. The amplified DNA was used to transform competent
E. coliDH5α [supE44 ΔlacU169 (ϕ80lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1]
(Invitrogen, Carlsbad, CA). Transformants were selected on Luria–Bertani (LB) agar plates
containing 75 μg ml−1 of ampicillin. Positive clones were identified by the restriction
endonuclease digestion pattern. Plasmid DNA was then isolated from one clone containing
each Cdt gene and transformed into E. coli BL21(DE3) [F− ompT hsdSB (rB− mB−) gal dcm
(DE3)] competent cells (Novagen). The DNA sequence of the insert in the selected plasmids
pJDA9, pJDB7 and pJDC2 (Table 2) was obtained to confirm that the cdt gene-containing
DNA fragments were cloned in the proper orientation and that no mutations were introduced
during PCR. Automated cycle sequencing reactions were conducted by the Genetics Core
Facility at the University of Pennsylvania using an Applied Biosystems 377 sequencer with
Dye Primer chemistry.
Construction and screening of a cdtA mutant library
The oligonucleotide primer pair cdtA-F/cdtA-R (Table 1) and pJDA9 DNA (Table 2) were
used with the GeneMorph Random Mutagenesis Kit (Stratagene), according to the
manufacturer's instructions, to generate a set of mutations, at low frequency, in the cdtA gene.
Mutated cdtA DNA fragments were then cloned into the NcoI and BamHI sites of pET15b and
transformed into Library Efficiency E. coli DH5α Competent Cells (Invitrogen). The
transformants were pooled, the plasmid DNA extracted and used to transform E. coli BL21
(DE3) competent cells. Individual colonies were transferred to master plates. Each
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transformant was grown in 10 ml of LB broth medium containing 75 μg ml−1 of ampicillin at
37°C with vigorous shaking. Isopropyl-β-D-thiogalactopyranoside (IPTG) (Sigma Chemicals,
St. Louis, MO) was added to a final concentration of 1 mM when the cultures reached late
logarithmic phase (OD600 = 0.8–1.0). The bacteria were grown an additional 4–5 h, collected
by centrifugation (6000 g for 10 min), washed with PBS and lysed at 4°C by sonication (three
bursts of 1 min duration at the low power setting; Braun-Sonic 2000, B. Braun Biotech,
Allentown, PA). The sonicates were centrifuged at 6000 g for 15 min to collect inclusion
bodies. Inclusion body pellets were suspended in 200 μl of PBS containing 6 M urea.
A CELISA, modified from that used by Lee et al. (2003), was used to evaluate binding of the
cdtA mutants. Briefly, CHO-K1 cells (1.5 × 104 cells well−11) were used to inoculate 96-well
plates (Mao and DiRienzo, 2002). The plates were incubated for 48 h at 37°C in an atmosphere
containing 5% CO2. The plates were washed with PBS containing 1 mM each MgCl2 and
CaCl2 and the cells fixed with 10% formalin for 15 min at room temperature. The inclusion
body fractions from the individual cdtA mutant library transformants described above were
mixed with 4 volumes of PBS containing 3% BSA (PBS-BSA). These preparations (100 μl)
were added to wells in triplicate. The plates were incubated at room temperature for 1 h, washed
three times with PBS and then fixed for 15 min at room temperature with 2% formaldehyde
and 0.2% glutaraldehyde. The plates were then washed three times with PBS containing 0.1%
Tween-20 (PBST) and incubated with PBS-BSA at room temperature for 1 h. A 1:3000 dilution
of anti-HisTag monoclonal antibody (Novagen) in PBS-BSA was added to the wells and the
plates incubated for 1 h at room temperature. The plates were washed three times with PBSBSA and incubation was continued with a 1:3000 dilution of anti-mouse IgG horseradish
peroxidase conjugate (Amersham Biosciences, Piscataway, NJ) for 1 h at room temperature.
The cells were washed three times with PBST followed by the addition of 100 μl of horseradish
peroxidase substrate ABTS-100 (Rockland, Gilbertsville, PA). The plates were read in a Perkin
Elmer HTS 7000 Bio Assay Reader (Boston, MA) at a wavelength of 405 nm. Absorbance
readings were compared with those obtained from triplicate wells containing inclusion body
fractions from E. coli BL-21(DE3) (pJDA9) and E. coli BL-21(DE3) (pET15b). There was no
detectable difference in CdtA-His6 binding to formalin fixed and non-fixed CHO cells (data
not shown).
Expression of the cdtA gene in the individual transformants was assessed by Western blotting.
Bacteria collected from 1 ml of IPTG-induced culture were mixed with 100 μl of gel loading
buffer (2% SDS, 0.05 M Tris-HCl (pH 6.8), 10% glycerol, 0.01% β-mercaptoethanol), and
heated in a boiling water bath for 5 min. Samples (20 μl per lane) were applied to a 10–20%
polyacrylamide Tris-HCl Ready Gel (Bio-Rad Laboratories, Hercules, CA). Following
electrophoresis, protein bands were transferred to a nitrocellulose membrane. The membrane
was blocked with 5% skim milk in TBS buffer [20 mM Tris-HCl (pH 7.6), 0.8% NaCl] for 1
h at room temperature with shaking. The membrane was washed and then incubated with antiHisTag monoclonal antibody (Novagen), diluted 1:3000 in TBS buffer, for 1 h at room
temperature with shaking. The filter was washed and incubated for 1 h with horseradish
peroxidase-conjugated anti-mouse IgG (Novagen) diluted 1:3000 in TBS buffer.
Immunopositive protein bands were detected with an Enhanced Chemiluminescence Western
Blotting Detection Kit (Amersham Pharmacia Biotech, Piscataway, NJ) according to the
manufacturer's instructions. Prestained molecular weight standards were obtained from New
England Biolabs (Beverly, MA). Lysates from E. coli BL-21(DE3) (pJDA9) and E. coli BL-21
(DE3) (pET15b) were used as positive and negative controls respectively.
Plasmid DNA was obtained from the mutant library cdtA clones using a QIAprep Miniprep kit
(QIAGEN, Valencia, CA). The plasmid DNA from each clone was digested with restriction
endonucleases NcoI and BamHI according to the manufacturer's instructions. The digested
samples were examined on 8% agarose gels to confirm the presence and size of the plasmid
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insert. DNA sequence analysis was performed by the Genetics Core Facility at the University
of Pennsylvania as described above.
Isolation of recombinant wild-type His6-tagged CdtA, CdtB and CdtC and mutant CdtA
subunit proteins
Recombinant clones E. coli BL-21(DE3) (pJDA9), E. coli BL-21(DE3) (pJDB7), E. coli BL-21
(DE3) (pJDC2) and individual clones from the cdtA mutant library were used to prepare the
three wild-type His-tagged Cdt protein subunits and mutated His-tagged CdtA proteins as
described previously (Mao and DiRienzo, 2002). Yield was approximately 2–4 mg protein per
100 ml of culture. The final dialysed protein preparations were passed through 45 micron filters
and quantified with the Micro BCA protein assay kit (Pierce, Rockville, IL). Purity was
assessed by analysis on 10–20% polyacrylamide gels. Aliquots of the quantified protein
samples were stored at −70°C in a buffer containing 10 mM Tris-HCl (pH 7), 100 mM NaCl,
5 mM MgCl2 and 5 mM imidazole.
Binding of recombinant wild-type His6-tagged CdtA, CdtB and CdtC and mutant CdtA subunit
proteins to CHO cells
Saturation binding kinetics were determined for wild-type CdtA-His6, CdtB-His6 and CdtCHis6 using 0–1.25 mg of each protein per millilitre in triplicate in the CELISA. To assess
binding activity purified His6-tagged wild-type and mutant proteins (1 μg well−1) were added
to triplicate wells in the CELISA. The 96-well plates were prepared and processed as described
above for screening of the transformants. These experiments were run a minimum of three
times.
Reconstitution and activity of wild-type and mutant CdtA-containing holotoxin
Wild-type holotoxin and holotoxin containing mutant CdtA-His6 proteins were reconstituted
as described previously (Mao and DiRienzo, 2002). The recombinant His6-tagged proteins
were mixed in equivalent proportions of wild-type CdtA-His6 or mutated CdtA-His6 with wildtype CdtB-His6 and CdtC-His6 and incubated for 1 h at 4°C in reconstitution buffer (10 mM
Tris-HCl (pH 7), 100 mM NaCl, 5 mM MgCl2). In some experiments holotoxin was
reconstituted with a CdtC-His6 mutant protein. This mutant, mutC41, was obtained by the same
methods used for creation of the CdtA mutant library (data not shown). This mutant had the
fewest nucleotide changes identified in the CdtC library [four nucleotide changes and two
amino acid substitutions (Q49L and S173C)].
Proliferation inhibition
To quantify the effects of reconstituted holotoxin on cell proliferation, CHO cells were seeded
in six-well tissue culture plates (300 cells in 3 ml of medium per well in triplicate) as described
previously (Mao and DiRienzo, 2002). Cell cultures were incubated for 4 h prior to addition
of the toxin to allow the cells to attach to the plates. Holotoxin preparations made with wildtype and mutant CdtA-His6 proteins (2.5 or 5 μg of total protein ml−1) were added to the CHO
cell cultures and the plates were incubated for 5–6 days to allow colonies to form. The medium
was then removed and the cells were fixed with 10% formalin. After incubation for 5 min, the
colonies were stained with crystal violet for 10 min, dried and counted. The number of colonies
per well was expressed as colonyforming units (cfu). A dose–response curve for wild-type
reconstituted holotoxin was also prepared using 0–2.5 μg of total protein ml−1. Due to limiting
amounts of purified proteins samples were run in duplicate wells. These experiments were run
twice.
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Cell cycle analysis
Cell cycle arrest was determined by flow cytometry as described previously (Kanno et al.,
2005). A dose–response curve was obtained with reconstituted wild-type holotoxin using 2.5,
5, 10 and 25 μg ml−1 of reconstituted wild-type holotoxin. CHO cells were treated with 10
μg ml−1 total protein of holotoxin made with mutant CdtA-His6 proteins. Cells were exposed
to the toxin in culture for 36 h. Propidium iodide stained nuclei were analysed on an
FACSCalibur flow cytometer at the University of Pennsylvania Cancer Center Flow Cytometry
and Cell Sorting Shared Resource facility. The data from 30 000 events were analysed with
ModFit 3.0 (Verity Software House, NH).
In vitro DNase activity
Supercoiled DNA nicking activity was determined, with minor modifications, as described
previously (Elwell and Dreyfus, 2000; Mao and DiRienzo, 2002). Briefly, 1 μg of supercoiled
pBluescript II SK(+) DNA was incubated with reconstituted holotoxin (500 ng of each subunit
protein per reaction) in 25 mM HEPES (pH 7.0) containing 50 mM MgCl2 at 37°C for 1 h.
Holotoxin was reconstituted with wild-type CdtB-His6 and CdtC-His6 and either wild-type
CdtA-His6 or one of the CdtA-His6 mutant proteins as described above except that incubation
was at room temperature for 1 h. In some reactions CdtC-His6 from mutC41 was used in place
of the wild-type subunit.
Glycoprotein ELISA
A glycoprotein ELISA assay was designed based on the immobilized glycoprotein binding
assay of McSweeney and Dreyfus (2005). Microtitre plates (96-well) were coated overnight
with 75 μg well−1 of thyroglobulin (Sigma). The plates were washed three times with PBST
followed by the addition of wild-type or mutant Cdt subunit proteins. All proteins were added
to triplicate wells at a concentration predetermined for each experiment (described below).
Plates were washed, treated with anti-His Tag monoclonal antibody and horseradish peroxidase
conjugate and were processed as described above for the CELISA. Saturation binding kinetics
were determined for wild-type CdtA-His6, CdtB-His6 and CdtC-His6 using 0–20 μg of each
protein per well. In other experiments, various combinations of subunit proteins using 4 μg of
CdtA-His6, 4.5 μg of CdtB-His6 and 3.5 μg of CdtC-His6 were added per well to assess
holotoxin assembly. In a third set of experiments, 10 μg of each subunit protein and each CdtAHis6 mutant protein was added per well to examine the ability of the mutant proteins to bind
to the glycoprotein. Competition experiments were performed by preincubating 4.5 μg of CdtBHis6 and 3.5 μg of CdtC-His6 with 4 μg of each mutant CdtA-His6 protein. Thyroglobulincoated plates were incubated with 4 μg of wild-type CdtA-His6 protein well−1 and the plates
were washed three times with PBST. The subunit protein mixtures were then added to the plates
and the plates processed as described above. An absorbance ratio was calculated by dividing
the average (triplicate wells) absorbance value of the CdtB-His6/CdtC-His6 protein or mutant
CdtA-His6 protein wells by the average absorbance value of wells containing only bound wildtype CdtA-His6. The binding experiments were repeated two to three times and, except for the
competition assay, were repeated with fetuin-coated plates.
Reconstitution (dialysis) assay
Dialysis membrane with a molecular weight exclusion limit of 100 kDa (Spectrum
Laboratories, Rancho Dominguez, CA) was soaked and rinsed in distilled water. Each of the
subunit proteins alone (100 μg of protein or mutant protein) or reconstituted heterotrimer (300
μg of total protein) were suspended in a total volume of 1 ml of refolding buffer containing
0.3 M urea. Each sample was dialysed against 800 ml of the same buffer for 48 h at 4°C with
two buffer changes. An aliquot (35 μl) of each protein or reconstituted protein sample was then
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examined, before and after dialysis, on Western blots as described above. Bands on Western
blots were quantified with ImageJ version 1.34 (http://rsb.info.nih.gov/ij/).
Computer analysis
The European Molecular Biology Open Software Suite (EMBOSS 2.9.0) (http://
emboss.sourceforge.net) was used to obtain amino acid sequence alignments and to calculate
isoelectric points (pI) and hydropathy (Kyte and Doolittle, 1982; Rice et al., 2000). Deduced
amino acid sequences of wild-type and mutant A. actinomycetemcomitans recombinant CdtAHis6 and CdtC-His6 were from nucleic acid sequences obtained during this study. The H.
ducreyi CdtA sequence was from GenBank (Accession number U53215).
The crystal structure of the H. ducreyi Cdt (NeŠić et al., 2004) was modelled in the software
program iMol 0.30 (http://www.pirx.com/iMol/). Coordinates were obtained from the Protein
Data Bank (Accession number 1SR4).
Statistical methods
Mean values and standard deviations were plotted where appropriate. The paired t-test was
used to evaluate the data in some experiments.
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Fig. 1.

Effect of point mutations on CdtA binding to CHO cells. Affinity-purified CdtA mutant
proteins were incubated with CHO cells in a CELISA. A. Saturation curves of wild-type
recombinant CdtA-His6, CdtB-His6, CdtC-His6 and total soluble protein from E. coli BL-21
(DE3) (pET15b) in a CELISA. Bound Cdt protein subunit was detected with anti-HisTag
monoclonal antibody (1:3000 dilution) and anti-mouse IgG horseradish peroxidase conjugate
(1:3000 dilution). B. Recombinant CdtA-His6 mutant proteins (1 μg well−1) were incubated
with CHO cells in a CELISA. Bound protein was detected as in the experiment in A and
compared with wells containing wild-type CdtA-His6, CdtB-His6 and CdtC-His6. Amino acid
substitutions are shown for each mutant. All samples were run in triplicate. Statistically
significant differences between the mutants and wild-type CdtA-His6 are marked with asterisks
(P < 0.005*, P < 0.01**). Results are representative of three trials.
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Fig. 2.

Effect of point mutations on CdtA binding to thyroglobulin. A. Saturation curves of the binding
of wild-type recombinant CdtA-His6, CdtB-His6, CdtC-His6 to thyroglobulin-coated wells in
ELISA. Bound protein was detected as described in the legend to Fig. 1. B. Affinity-purified
recombinant CdtA-His6 mutant proteins (10 μg well−1) were added to wells coated with
thyroglobulin. Bound protein was detected as in the experiment in A and compared with wells
containing 10 μg well−1 of wild-type CdtA-His6, CdtB-His6 and CdtC-His6. Amino acid
substitutions are designated for each mutant. All samples were run in triplicate. Statistically
significant differences between the absorbance values for mutant and wild-type CdtA-His6 are
marked with an asterisk (P < 0.005). Results are typical of three trials.
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Fig. 3.

Effect of point mutations in CdtA on the proliferation of CHO cells treated with reconstituted
holotoxin. A. Wild-type recombinant CdtA-His6, CdtB-His6 and CdtC-His6 (1:1:1 by weight)
were preincubated in folding buffer and increasing concentrations of the mixture was added
to CHO cell cultures. Cell colonies were stained and counted after 6 days and the data expressed
as cfu. B. Holotoxin was reconstituted as in the experiment in A except that recombinant CdtAHis6 mutant proteins were substituted for wild-type CdtA-His6. In some samples a CdtCHis6 mutant (mutC41) was substituted for wild-type CdtC-His6. Amino acid substitutions are
shown for each mutant. MutC41 contained two amino acid substitutions. CdtA-H designates
holotoxin reconstituted with wild-type CdtA-His6. All samples were run twice in single wells.
Twice the amount of CdtA-His6 protein (5 μg ml−1) was used to treat some cultures. Cfu were
obtained as in A and the data is expressed as the percent of input CHO cells.
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Fig. 4.

Effect of point mutations in the cdtA gene on the cell cycle of CHO cells treated with
reconstituted holotoxin. A. CHO cell cultures (1 × 106) were treated with 0, 2.5, 5.0, 10.0 and
25.0 μg of total holotoxin protein ml−1. Holotoxin was reconstituted from wild-type CdtAHis6, CdtB-His6 and CdtC-His6 (1:1:1) for 36 h post intoxication. DNA profiles obtained by
FACS analysis of propidium iodide stained nuclei are shown (solid line). G0/G1 (2n) and G2/
M (4n) (solid filled) and S (diagonal line filled) peaks where determined by computer analysis.
B. Dose–response curve of the percentage of cells having a 4n DNA content after treatment
with each holotoxin concentration. C. CHO cell cultures were treated as in A except that 10
μg of total mutant CdtA or CdtC holotoxin protein ml−1 was used. Panels a, mutA65; b,
mutA81; c, mutA99; d, mutA112; e, mutA121; f, mutA221; g, mutA239; h, mutA241; i,
mutC41. Results are representative of two experiments.
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Fig. 5.

Effect of point mutations in the cdtA gene on the in vitro DNA nicking activity of reconstituted
holotoxin. A. Wild-type Cdt subunit proteins alone and in various combinations were incubated
with pBluescript II SK(+) DNA under conditions optimized for CdtB-His6 nuclease activity
(Experimental procedures). B. Holotoxin prepared with protein from each of the CdtA-His6
mutants and from mutC41 was incubated with plasmid DNA as in A. Samples were examined
on 0.8% agarose gels stained with ethidium bromide. Supercoiled (S), linear (L) and relaxed
(R) forms of DNA are labelled. Results are representative of three experiments.
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Fig. 6.

Competitive binding of mutant CdtA-His6 proteins to CdtB-His6 and CdtC-His6. A. Subunit,
heterodimer and heterotrimer binding to thyroglobulin. ELISA plates were coated with
thyroglobulin followed by the addition of individual or a combination of wild-type subunit
proteins. B. Competition assay. ELISA plates were coated with thyroglobulin followed by 4
μg well−1 of wild-type CdtA-His6. Individual wild-type CdtB-His6 and CdtC-His6 subunit
proteins, a preincubated mixture of CdtB-His6 with CdtC-His6 and preincubated mixtures of
the mutant CdtA-His6 proteins with wild-type CdtB-His6 and CdtC-His6 were added to the
plates. The plates were developed and the absorbance determined as described in the legend
to Fig. 1. All samples were run in triplicate. Absorbance ratios based on the binding of wildtype CdtA-His6 to thyroglobulin were calculated as described in Experimental procedures. A
statistically significant increase in the absorbance values for the homodimers and heterotrimer
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relative to that of wild-type CdtA-His6 are marked with an asterisks (P < 0.005*, P < 0.01**).
Results are representative of two experiments.
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Fig. 7.

Effect of point mutations in the cdtA gene on the reconstitution of holotoxin. Individual wildtype subunit proteins and heterotrimers composed of preincubated mixtures of either wild-type
or mutant CdtA-His6 proteins were dialysed for 48 h. The protein composition of the material
in the dialysis bag, before and after dialysis, was then examined by Western blotting as
described in the Experimental procedures. BD, before dialysis; AD, after dialysis.
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Fig. 8.

Alignment of A. actinomycetemcomitans recombinant CdtA-His6 (pJDA9), H. ducreyi CdtA
(GenBank Accession number U53215) and CdtA-His6 mutant deduced amino acid sequences
(Table 3). Identical residues are boxed. The positions of the four amino acid substitutions in
the aromatic patch (ap) mutant described in reference 24 are marked. Amino acid resides 18–
56 were disordered in the crystal structure (NeŠić et al., 2004). The arrow marks the aminoterminal end of the 17–18 kDa form of CdtA identified in several studies (Frisk et al.,
2001;Saiki et al., 2004;Shenker et al., 2004). The solid line between the two sequences marks
the region conserved among the various CdtA proteins (Lee et al., 2003).
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Fig. 9.

Location of the amino acid substitutions of the CdtA-His6 mutant proteins in the crystal
structure of the H. ducreyi Cdt. The coordinates (Protein Data Bank Accession number 1SR4)
for the crystal structure (NeŠić et al., 2004) were computer modelled. A–C. Orientation of the
CdtA, CdtC and CdtB subunits respectively. The amino-(N) and carboxy-(C) terminal residues
in CdtA and CdtC and the theoretical active site in CdtB are labelled. D. Locations of the seven
unique amino acid substitutions (black text) in the A. actinomycetemcomitans recombinant
CdtA-His6 mutants that affected binding are shown at the positions of the corresponding
residues in the H. ducreyi sequence. The positions of the three substitutions that resulted in a
non-cytotoxic phenotype are underlined. The CdtA used to crystalize the H. ducreyi Cdt
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contained residues 18–223 to eliminate a putative secretory signal sequence (NeŠić et al.,
2004). Residues 18–56 were disordered in the crystal structure. The two amino acid
substitutions in the CdtC-His6 mutant (mutC41) are shown in red. E. Location of the four amino
acid substitutions in the aromatic patch (AP) region mutant of NeŠić et al. (2004). F. Locations
of the four cysteine residues in CdtA. These cysteines are conserved in the A.
actinomycetemcomitans and H. ducreyi CdtA.
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Table 1

Oligonucleotide primers used for cdtA-His, cdtB-His and cdtC-His cloning.
Name

Sequencea

cdtA-F
cdtA-R
cdtB-F
cdtB-R
cdtC-F
cdtC-R

5′-CCCACCCATGGCTCCGAGGAGAGGTACAATGAAAAAG-3′
5′-TTAGGATCCGTGGTGGTGGTGGTGGTGATTAACCGCTGT-3′
5′-GCCGCCGCGGTTCCATGGAATGGGTAAAGC-3′
5′-TTAGGATCCGTGGTGGTGGTGGTGGTGGCGATCATGAA-3′
5′-TCCCGCCGGTTTTGTCCATGGTCGCTAAGGAGAATAC-3′
5′-AATGGATCCGTGGTGGTGGTGGTGGTGGCTACCCTGATT-3′

a

Underlined bases mark the NcoI and BamHI restriction endonuclease recognition sites. Bases in bold type mark the codons for the His-tag.
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Table 2

Plasmids used in this study.
Plasmid

Features

Source or reference

pCDT1
pJDA9
pJDB7
pJDC2
pMUT65cdtA
pMUT81cdtA
pMUT99cdtA
pMUT112cdtA
pMUT121cdtA
pMUT221cdtA
pMUT239cdtA
pMUT241cdtA
pMUT41cdtC
pET15b

cdt locus from A. actinomycetemcomitans cloned in E. coli
cdtA gene containing 6 His codons at 3′-end
cdtB gene containing 6 His codons at 3′-end
cdtC gene containing 6 His codons at 3′-end
CdtAC196S
CdtAS165N
CdtAT88T
CdtAF43S
CdtAT41A
CdtAC178W
CdtAP56Q
CdtAT219A
CdtC
Cloning vector

Mayer et al. (1999)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
Novagen

Mol Microbiol. Author manuscript; available in PMC 2006 April 10.

Cao et al.

Page 30

Table 3

Summary of point mutations.
Mutant designation

Nucleotide change

Amino acid change

mutA62
mutA65
mutA79
mutA81
mutA99
mutA112
mutA121
mutA183
mutA221
mutA238
mutA239
mutA241
mutA249
mutC41

A54C
A198T/T589A
G348A
T452A
T264A
T128C/A246G
A121G
G177A
T534G
C142T
C166A
A655G
A655G
A146T/A261G/
T430C/A517T/

None
None/C197S
None
S165N
None
F43S/none
T41A
None
C178W
None
P56Q
T219A
T219A
Q49L/none
None/S173C

Position in H.
ducreyi CdtA
–
C198
–
S166
–
P43
I41
–
C179
–
S56
T220
T220
NA

NA, not applicable.
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Table 4

Cell cycle analysis of CHO cells treated with reconstituted mutant holotoxin.
Form of CdtA

Diploid G1 (2n) (%)

Diploid G2 (4n) (%)

Diploid S (%)

Coefficient of variance
(%)

none
CdtA-H
mutA65
mutA81
mutA99
mutA112
mutA121
mutA221
mutA239
mutA241
mutC41

75.35
15.42
4.79
36.44
8.71
9.81
73.74
68.04
4.90
7.97
66.03

5.93
66.00
70.85
43.91
78.14
79.11
9.92
14.86
79.28
79.25
15.43

18.72
18.59
24.37
19.65
13.16
11.08
16.34
17.10
15.81
12.79
18.54

2.71
4.18
9.87
3.34
5.04
4.22
3.32
3.73
5.99
4.32
3.78
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